Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media

© dkfz.de

Primary CNS tumors are relatively rare accounting for approximately 2-3% of all cancers. However, they comprise aggressive malignancies with a very poor prognosis and are responsible for 7% cancer deaths in the population younger than 70 years. The age distribution of CNS neoplasias is bimodal with a first peak in children, accounting for more than one fifth of all tumor diseases in children and a second one in adults between 45-70 years of age. In both groups surgical resection of tumors from vital brain structures constitutes a major clinical and ethical challenge, emphasizing the need for efficacious adjuvant therapies. Therefore, faithful mouse models which allow preclinical target validation are a major challenge for translational brain cancer research.

to top
powered by webEdition CMS